Implementation of share capital reduction and reverse share split

In accordance with the resolution by the ordinary general meeting on 23 May 2013, DiaGenic ASA has completed the reduction of share capital by NOK 39,167,390.40, from NOK 40,799,365 to NOK 1,631,974.60.

The ordinary general meeting on 23 May 2013 resolved a reverse share split in the ratio 10:1, so that ten shares are consolidated into one share. The reverse share split will be effective from and including Friday 16 August 2013 (ex date). The last trading day prior to the reverse share split is today, Thursday 15 August 2013.

Following the share capital reduction and the reverse share split, the Company’s share capital is NOK 1,631,974.60, divided into 8,159,873 shares, each with a par value of NOK 0.20.

For more information please contact:

Paul de Potocki, CEO

Telephone: +47 2324 8950

Ruben Ekbråten, CFO

Telephone: +47 2324 8950

About DiaGenic ASA

DiaGenic is an innovative Norwegian diagnostic company that seeks to create value for patients, partners and investors by developing innovative and patient friendly in vitro diagnostic (IVD) products for early detection of diseases. The company’s proprietary concept implies that a disease evokes systemic responses in the blood unique for the disease, and which can be measured by using a blood sample. DiaGenic is a world leader in identifying gene expression signatures in blood and is focused on the development of IVD biomarker products in the field of Alzheimer’s disease. The company protects its technology through an extensive patent portfolio. DiaGenic is listed on the Oslo Stock Exchange. For more information please visit: www.diagenic.com